Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo

• Published in: Journal of controlled release 2015-09, Vol.213, p.128-133
• Main Authors: Cote, Brianna, Carlson, Lisa Janssen, Rao, Deepa A., Alani, Adam W.G.
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - adverse effects; Antibiotics, Antineoplastic - pharmacology; Antioxidants - administration & dosage; Antioxidants - pharmacology; Cardiotonic Agents - administration & dosage; Cardiotonic Agents - pharmacology; Cardiotoxicity; Cardiotoxicity - drug therapy; Cell Line; Cell Line, Tumor; Chemosensitization; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Doxorubicin - pharmacology; Drug Carriers - chemistry; Female; Heart - drug effects; Humans; Male; Micelles; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Natural products; Poloxamer - chemistry; Polymeric micelles; Quercetin - administration & dosage; Quercetin - pharmacology; Rats; Reactive Oxygen Species - metabolism; Stilbenes - administration & dosage; Stilbenes - pharmacology
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2015.06.040

Doxorubicin hydrochloride (ADR) is an anthracycline antibiotic used to treat various cancers. However, due to its extensive cardiotoxic side effects a lifetime cumulative dose limit of 450–550mg/m2 exists. The postulated mechanism of the cardiotoxicity is generation of reactive oxygen and nitrogen species. Natural products like resveratrol (RES), and quercetin (QUE) are known free radical scavengers and have shown cardioprotective effects. However, concurrent dosing of these natural products with ADR is limited due to their low solubility, and low oral bioavailability. We hypothesize that the combination of RES and QUE in Pluronic® F127 micelles (mRQ) when co-administered with ADR, will be cardioprotective in vitro and in vivo, while maintaining or increasing the efficacy of ADR against cancer cell lines in vitro. We prepared mRQ micelles capable of retaining 1.1mg/mL and 1.42mg/mL of RES and QUE respectively. The in vitro release of RES and QUE from the micelles followed first order kinetics over 48h. In vitro cell viability and combination index analysis studies in human ovarian cancer cells (SKOV-3) and rat cardiomyocytes (H9C2) showed that RES:QUE: ADR at 10:10:1 ratio was synergistic in SKOV-3 cells and antagonistic in H9C2 cells. Caspase 3/7 activity studies indicated that mRQ did not interfere with ADR caspase activity in SKOV-3 cells but significantly decreased it in H9C2 cells. The generation of reactive oxygen species (ROS) in SKOV-3 and H9C2 cells in the presence of mRQ also indicated no changes in ROS activity in SKOV-3 cells but significant scavenging in H9C2 cells. Healthy mice were exposed to acute doses of ADR and ADR with mRQ. Based on biochemical estimations the presence of mRQ with ADR conferred full cardioprotection in these mice. Concurrent administration of mRQ with ADR at 10:10:1 ratio provides a viable strategy to mitigate acute ADR induced cardiotoxicity. [Display omitted]